These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone. Plotnikoff NP; Prange AJ; Breese GR; Anderson MS; Wilson IC Science; 1972 Oct; 178(4059):417-8. PubMed ID: 4627781 [TBL] [Abstract][Full Text] [Related]
24. Study on the antinociceptive action of Tyr-K-MIF-1, a peptide from the MIF family. Zamfirova R; Bocheva A; Dobrinova Y; Todorov S Auton Autacoid Pharmacol; 2007 Apr; 27(2):93-8. PubMed ID: 17391278 [TBL] [Abstract][Full Text] [Related]
25. The influence of alpha-adrenergic drugs on catalepsy induced by haloperidol or fluphenazine in rats. Wielosz M; Kleinrok Z; Włoch K; Zebrowska-Lupina I Pol J Pharmacol Pharm; 1978; 30(5):653-8. PubMed ID: 35783 [TBL] [Abstract][Full Text] [Related]
26. [Central action of melanostatin and the opiate system of the brain]. Chepurnova NE; Klusha VE; Borzenkov VM; Lapishin DN; Khatskelevich AIa Fiziol Zh SSSR Im I M Sechenova; 1985 Aug; 71(8):937-44. PubMed ID: 2865175 [TBL] [Abstract][Full Text] [Related]
27. Potentiation of apomorphine action in rats by l-prolyl-l-leucyl-glycine amide. Kostrzewa RM; Kastin AJ; Sobrian SK Pharmacol Biochem Behav; 1978 Sep; 9(3):375-8. PubMed ID: 30981 [TBL] [Abstract][Full Text] [Related]
28. Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats. Pulvirenti L; Kastin AJ Eur J Pharmacol; 1988 Jul; 151(2):289-92. PubMed ID: 2901971 [TBL] [Abstract][Full Text] [Related]
29. The effects of a hypothalamic peptide factor, MIF and its cyclic analog on tolerance to haloperidol in the rat. Bhargava HN Life Sci; 1981 Jul; 29(1):45-51. PubMed ID: 6115301 [No Abstract] [Full Text] [Related]
30. [Functional state of the sympathetic-adrenal system in melanocyte-stimulating hormone deficiency under the effect of the melanocyte-inhibiting factor of the hypothalamus]. Mel'nik BE; Robu AI; Paladiĭ ES Probl Endokrinol (Mosk); 1980; 26(2):57-60. PubMed ID: 6103533 [TBL] [Abstract][Full Text] [Related]
32. Synthetic MIF analogues. Part I: synthesis by four-component condensation (4 CC) and classical methods. Failli A; Sestanj K; Immer HU; Götz M Arzneimittelforschung; 1977; 27(12):2286-9. PubMed ID: 23794 [TBL] [Abstract][Full Text] [Related]
33. Alpha-MSH and MIF-2 effects on serotonin levels and accumulation in various rat brain areas. Spirtes MA; Kostrzewa RM; Kastin AJ Pharmacol Biochem Behav; 1975; 3(6):1011-5. PubMed ID: 4814 [TBL] [Abstract][Full Text] [Related]
34. Pharmacological studies with a tripeptide, prolyl-leucyl glycine amide. Plotnikoff NP; Kastin AJ Arch Int Pharmacodyn Ther; 1974 Oct; 211(2):211-24. PubMed ID: 4156639 [No Abstract] [Full Text] [Related]
35. MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders. Sandyk R Int J Neurosci; 1990 May; 52(1-2):59-65. PubMed ID: 1979968 [TBL] [Abstract][Full Text] [Related]
36. Proceedings: Effects of peptides regulating the release of MSH and TSH and of some analogues on the spontaneous exploratory reactions in rats. Krejcí I; Kupková B; Kasafírek E; Jost K Act Nerv Super (Praha); 1975; 17(4):282-3. PubMed ID: 3938 [No Abstract] [Full Text] [Related]